11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes
Status:
Unknown status
Trial end date:
2021-10-12
Target enrollment:
Participant gender:
Summary
To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh
compound B (PiB) retention, to the progression of cognitive impairments in patients with
Parkinson's disease(PD).